Drug Profile
Infliximab biosimilar - Prestige BioPharma
Alternative Names: PBP 1505; Remicade biosimilar - Prestige BioPharmaLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Prestige BioPharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arthritis
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Arthritis in Singapore (Parenteral)
- 17 Jan 2017 Early research in Arthritis in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)